Tech Company Financing Transactions
iDEL Therapeutics Funding Round
On 3/17/2026, iDEL Therapeutics raised $10 million in Seed funding from BioMed Ventures, Gründerfonds Ruhr and KHAN Technology Transfer Fund.
Transaction Overview
Company Name
Announced On
3/17/2026
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its development efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Otto-Hahn-Straße 15
Dortmund, 44227
Germany
Dortmund, 44227
Germany
Phone
Website
Email Address
Overview
iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism. Using our synthetic shuttle platform, we aim to unlock previously undruggable intracellular targets, broaden therapeutic windows, and expand treatment options for patients across a range of indications. The company is focused on advancing its pipeline toward the clinic while building scalable value through strategic partnerships.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Marcus Kostka
Chief Scientific Officer
Jürgen Moll
Chief Technical Officer
Andreas Briel
VP - Bus. Development
Torsten Mummenbrauer
Browse more venture capital transactions:
Prev: 3/17/2026: Rubi Laboratories venture capital transaction
Next: 3/17/2026: V-Glass venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs